United States Brachytherapy Devices Market 2026 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Brachytherapy Devices Market reached US$ 1,024.1 million in 2024 and is expected to reach US$ 1,902.7 million by 2033, growing at a CAGR of 7.2% during the forecast period 2025-2033

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/brachytherapy-devices-market?sb

Key Development:

United States: Recent Industry Developments

✅ In January 2026, Elekta hosted a strategic update highlighting ongoing innovation and commitment to expanding brachytherapy device capabilities within its precision oncology portfolio, reinforcing its focus on internal radiation therapy solutions and workflow improvements across high‐dose‐rate and image‐guided workflows.

✅ In January 2026, imaging specialist Elekta announced enhanced Mosaiq connectivity for its microSelectron digital brachytherapy afterloader systems, aimed at improving treatment planning and clinical workflow integration for internal radiation therapy across U.S. cancer centers.

✅ In January 2026, Esteya electronic brachytherapy systems received renewed attention with first U.S. installations scheduled following their FDA 510(k) clearance, marking expanded access for less invasive skin cancer brachytherapy treatments in clinical settings.

✅ In December 2025, research and pilot work on novel interstitial brachytherapy tools such as the OncoReach steerable stylet were presented in early clinical evaluations, demonstrating innovation in device design that may enhance catheter placement precision in HDR procedures.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=brachytherapy-devices-market

Japan: Recent Industry Developments

✅ In January 2026, Japan's Ministry of Health regulators reportedly gave deliberative approval for the Alpha DaRT System for recurrent head and neck cancer, with final sign‐off expected imminently, signaling one of the first internal radiation therapy devices potentially entering the Japanese market under post‐marketing evaluation conditions.

✅ In January 2026, the University of Tokyo and Fujitsu launched trials optimizing brachytherapy workflow integration with imaging technologies to support clinical implementation and procedural efficiency, underscoring collaborative efforts in device usage and treatment accuracy improvements.

✅ In November 2025, PDRadiopharma confirmed plans to exhibit new radiopharmaceutical manufacturing technology at major nuclear medicine conferences in Kyoto, showcasing advanced oncology device technologies anticipated to support emerging internal radiation therapy solutions.

✅ In late 2025, Japan's brachytherapy device market outlook highlighted increased adoption of AI‐driven imaging and treatment planning systems to enhance precision and workflow efficiency, reflecting strategic investment trends and advanced treatment planning innovation in the regional device landscape.

Key Players:

=> Elekta AB, Varian Medical Systems, Inc., Eckert & Ziegler, Theragenics Corporation, Becton, Dickinson, and Company, BEBIG Medical, Sun Nuclear Corporation, CIVCO Medical Solutions and among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/brachytherapy-devices-market?sb

Key Segments:

By Dosage Type

High-Dose Rate (HDR) Brachytherapy leads with 55% share, driven by its precision, shorter treatment duration, and growing adoption in oncology centers worldwide. Low-Dose Rate (LDR) Brachytherapy accounts for 45%, supported by its established use in prostate and gynecological cancers, especially in regions with mature radiotherapy infrastructure.

By Product Type

Seeds hold the largest share at 40%, fueled by demand in prostate, breast, and cervical cancer treatments. Brachytherapy Applicators represent 25%, reflecting their critical role in accurate radiation delivery. Brachytherapy Afterloaders account for 20%, supported by adoption in advanced radiotherapy centers. Electronic Brachytherapy holds 15%, driven by minimally invasive procedures and emerging use in skin and breast cancer therapies.

By Technique Type

Ultrasound-Guided Brachytherapy dominates with 35% share, due to real-time imaging and ease of use in prostate and gynecological applications. MRI-Guided Brachytherapy accounts for 25%, favored for its precision in soft tissue visualization. CT-Guided Brachytherapy holds 20%, supported by broader availability and integration with conventional oncology workflows. PET-Guided Brachytherapy represents 10%, reflecting niche applications in research and advanced cancer centers. Others make up 10%, including hybrid and emerging imaging-guided techniques.

By Application

Prostate Cancer leads with 30% share, driven by high prevalence and effectiveness of brachytherapy in treatment protocols. Gynecological Cancer accounts for 20%, supported by widespread adoption in cervical and uterine cancer therapies. Breast Cancer represents 15%, fueled by precision-targeted radiation. Skin Cancer holds 10%, Cervical Cancer accounts for 10%, and Others make up 15%, including head & neck, liver, and esophageal cancers.

By End-User

Hospitals dominate with 50% share, due to well-equipped oncology departments and integrated radiotherapy services. Radiotherapy Centers hold 20%, reflecting specialized focus on cancer treatment. Diagnostic Centers represent 15%, supported by imaging-guided brachytherapy planning. Ambulatory Surgical Centers account for 10%, reflecting growing outpatient oncology procedures. Others make up 5%, including research institutes and specialty clinics.

By Region

North America - 35% Share
North America leads with 35%, driven by advanced radiotherapy infrastructure, strong adoption of HDR brachytherapy, and high cancer prevalence in the U.S. and Canada.

Europe - 30% Share
Europe holds 30%, supported by established oncology centers, government healthcare support, and widespread use of imaging-guided brachytherapy in Germany, France, the U.K., Italy, and Spain.

Asia-Pacific - 20% Share
Asia-Pacific accounts for 20%, fueled by increasing cancer incidence, expanding hospital infrastructure, and adoption of modern radiotherapy techniques in China, India, Japan, South Korea, and Australia.

South America - 8% Share
South America represents 8%, driven by rising investment in oncology infrastructure, growing awareness of brachytherapy, and adoption in Brazil, Argentina, and Chile.

Middle East & Africa - 7% Share
The Middle East & Africa hold 7%, supported by emerging cancer centers, government initiatives in healthcare, and expanding access to HDR brachytherapy in GCC countries, South Africa, and surrounding regions.

FAQ

What is the current size of the Brachytherapy Devices Market?

A: In 2024, the Brachytherapy Devices Market was valued at US$ 1,024.1 million, reflecting its strong industry presence.

Q2: How large is the Brachytherapy Devices Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Brachytherapy Devices Market will grow to around US$ 1,902.7 million, demonstrating significant expansion.

Q3: What is the growth rate of the Brachytherapy Devices Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.2% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.